The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation  by Habib, George et al.
Respiratory Medicine (2014) 108, 1641e1646Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/rmedThe impact of corticosteroid treatment on
hemoglobin A1C levels among patients with
type-2 diabetes with chronic obstructive
pulmonary disease exacerbation
George Habib a,b,*, Yusri Dar-Esaif c, Hashim Bishara d,
Suheil Artul e, Samih Badarny f, Mark Chernin a, Adel Jabbour ga Department of Medicine, Carmel Medical Center, Haifa, Israel
b Rheumatology Clinic, Nazareth Hospital, Nazareth, Israel
c Department of Medicine, Nazareth Hospital, Nazareth, Israel
d Pulmonary Unit, Nazareth Hospital, Nazareth, Israel
e Department of Radiology, Nazareth Hospital, Nazareth, Israel
f Department of Neurology, Carmel Medical Center, Haifa, Israel
g Central Lab, Nazareth Hospital, Nazareth, IsraelReceived 12 February 2014; accepted 13 August 2014
Available online 22 August 2014KEYWORDS
Hemoglobin A1c;
Chronic obstructive
pulmonary disease
exacerbation;
Corticosteroids;
Diabetes* Corresponding author. Department
043.
E-mail address: gshabib@gmail.com
http://dx.doi.org/10.1016/j.rmed.201
0954-6111/ª 2014 Elsevier Ltd. All rigSummary
Background: Corticosteroid-induced hyperglycemia is a known adverse effect. There are no
studies on the impact of corticosteroid treatment on hemoglobin A1c (HbA1c) levels in type-
2 diabetes patients with chronic obstructive pulmonary disease (COPD) exacerbation.
Methods: HbA1c levels were evaluated in type-2 diabetes patients with COPD exacerbation on
admission to the hospital (group-1) and 3-months later. Demographic, clinical, laboratory vari-
ables and total steroid dose were documented. Age- and sex-matched group of type-2 diabetes
patients with COPD who were admitted for other reasons (group-2), were asked to participate
as a control group. ManneWhitney and Chi square/Fischer’s exact tests were used to compare
between the parameters of the two groups. Wilcoxon’s signed rank test was used to compare
between HbA1c levels at baseline and 3 months later. Multi-variate linear regression analysis
was used to find predictors for a change in HbA1c levels in group-1 patients.
Results: 23 and 21 patients in groups 1 and 2 respectively, completed the study. There were 39
male (w89%) patients. Mean age of the patients was 66.2  8.2 years. In both groups, anti-
diabetic management was augmented. There was no significant change in the HbA1c levels
in group-1 (p Z 0.416), however there was a significant decrease in HbA1c levels in group-2of Medicine, Carmel Medical Center, Haifa 34362, Israel. Tel.: þ972 (4) 8250 757; fax: þ972 (4) 8250
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1642 G. Habib et al.(p Z 0.032). Total dose of steroids was a predictor for an increase in HbA1c levels in group-1
patients (p Z 0.026).
Conclusions: Type-2 diabetes patients who were treated with steroids for COPD exacerbation
had no significant change in HbA1c levels. Total dose of steroids was a predictor for an increase
in HbA1c levels.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Corticosteroids are an important component in the treat-
ment of patients with chronic obstructive pulmonary dis-
ease (COPD) exacerbation [1]. The mechanism of action is
believed to be through suppression of airway inflammation
[2]. It can be given either orally or intravenously at a dose
of about 30e60 mg/d of prednisone equivalent for about
one week and stopped or tapered gradually [3].
Corticosteroids-induced hyperglycemia is a well-known
adverse effect of glucocorticoid treatment [4]. It could
occur in both diabetic and non-diabetic patients, and has a
high incidence rate among patients in hospital [5,6]. This
effect is mediated mainly through increased insulin resis-
tance [6]. Some studies had shown also decreased insulin
secretion [7,8]. There are quite many reports about the
management and monitoring of corticosteroid-induced hy-
perglycemia [9,10]. Strategies including augmenting or
starting insulin treatment, starting other oral antidaibetic
meds or splitting the dose of corticosteroids were
recommended.
Hemoglobin A1c (HbA1c) is an accepted indicator of
blood glucose control. It reflects the mean blood glucose
levels over a period of about 2e3 months [11]. Patients with
diabetes and COPD are a special group. These patients are
at risk of exposures to steroid treatment at the time of
COPD exacerbation. There are no studies in the literature
about the impact of corticosteroid treatment during COPD
exacerbation on HbA1c levels among patients with dia-
betes. In this case-control study we wanted to evaluate the
effect of steroid treatment on HbA1c level among patients
with type-2 diabetes admitted to the hospital with COPD
exacerbation.
Methods
Non-selected patients with type-2 diabetes who were
admitted to the emergency room at the Nazareth hospital
with COPD exacerbation were asked to participate in our
study (group-1) (all the patients with COPD exacerbation in
the Nazareth Hospital were admitted later to the medical
ward). After consent, blood was drawn for HbA1c levels and
patient’s demographic, clinical and laboratory variables
including age, sex, body mass index (BMI), duration of
diabetes, type of anti-diabetic therapy, type of diet, his-
tory of cardiovascular events, number of smoked cigarettes
(pack/year), room air PCO2 level, room air O2 saturation
level, serum creatinine, c-reactive protein (CRP) level and
blood white cell count (WBC) were documented on
admission.Age- and sex-matched patients with type-2 diabetes and
COPD who were admitted to the medical ward for causes
other than COPD exacerbation (group-2) were asked to
participate in our study as a control group.
The diagnosis of DM was based on official medical doc-
uments from the patient’s physician showing levels of blood
glucose above 126 mg/dl in the morning following fast of at
least 8 h, in at least two occasions.
Patients were diagnosed with COPD according to the
strategy of the Global initiative for COPD, and the diag-
nosis of COPD exacerbation was based on an acute in-
crease of symptoms of COPD beyond normal day-to-day
variation [12].
The diagnosis of ischemic heart disease (IHD), cerebro-
vascular accident (CVA) or transient ischemic attack (TIA)
was based on official medical documents from the patient’s
physician. Renal impairment was defined when serum
creatinine level was higher than upper normal limit cor-
rected for age and gender.
The inclusion criteria included patients older than 18
year-old and patients who are able to sign a consent form.
The exclusion criteria included patients who were allergic
to corticosteroids, had any systemic, local or topical
corticosteroid treatment during the previous 3 months,
patients who started using, stopped or changed the dose of
steroid inhalers during the previous 3 months, patients who
changed their anti-diabetic treatment during the previous 3
month, patients who changed their carbohydrate diet dur-
ing the previous 3 months (evaluated by dietician), patients
who lost or gained weight by > 5% of their original weight
during the previous 3 months, or those who were unable to
provide a repeated blood sample for HbA1c 3 months
following the first one, for any reason.
In group-1 patients, the total dose of steroids was
documented daily during their hospital stay. In both groups
blood glucose levels were documented during hospital stay
and also the type and dose of anti-diabetic medications.
Following discharge, the patients from both groups were
called up weekly by phone and asked about steroid treat-
ment and dose, regimen of anti-diabetic meds and diet.
The total dose of steroids in group-1 included the total
dose during hospital stay plus the total dose taken after
discharge.
A rise of at least 20% of the dose or an initiation of new
anti-diabetic treatment, during hospital stay, was consid-
ered a significant augmentation of anti-diabetic treatment.
Like wise, a reduction of >20% of carbohydrate amount in
the diet during hospital stay, compared to pre-enrollment
level was considered a significant augmentation of anti-
diabetic management.
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HbA1c level was obtained from all the patients who
completed the study, as well as current BMI measurement.
Patients from group-2 (control group) who were given
systemic, local injection or topical steroids during the 3
months of follow up were excluded from further analysis.
Physicians, nurses and dietician on the medical ward
who took care of the patients in both groups, were unaware
of the study. Medical team and dietician participating in the
study were not involved in decision-making regarding
management of the patients of our study.
All the samples for HbA1c determination were analyzed
by the end of the study using COBAS INTEGRA 800 analyzer
with COBAS INTEGRA Hemolyzing Reagent Gen. 2. This
method uses TTAB as the detergent in the hemolyzing re-
agent. The HbA1c determination was based on the turbi-
dimetric inhibition immunoassay (TINIA) for hemolyzed
whole blood. The technician who analyzed the samples at
the end of the study was blinded to the group patient
belonged to.
Due to limited funding, it was decided “appriori” that
each group would include 25 patients.
For statistical analysis the ManneWhitney and Chi
square/Fischer’s exact tests were used to compare be-
tween the different parameters of the two groups. The
Wilcoxon’s signed rank test was used to compare between
the changes of HbA1c within each group. A multi-variate
linear regression analysis was used to correlate between
the different clinical and laboratory variables of theTable 1 Patients’ characteristics in both groups at baseline.
Group
Parameter Group-1 (No. of patients Z
- Agea 66.22  8.2, 49e81
- Gender (M:F) 20:3
- BMIa 31.90  7.14, 17.37e47.4
- Duration of diabetesa,c 8.8  10.42, 1e40
- Type of antidiabetic treatment
Oral hypoglycemic 17
Insulin alone 4
Combination 7
Diet only 2
- Smokers (present/past) 22
- Amount of smokinga,b 70.11  32.30, 30e172
- Inhaled steroids users 18
- Fever 4
- Pneumonia 2
- PCO2
a 52.30  12.8, 35e67.4
- O2 saturation
a 91.22  9.1, 65e98
- HbA1ca 7.7%  1.7, 6.1e11
- WBCa 9.48  3.89, 5.88e21.5
- CRP levelsa 5.96  5.70, 1.03e29.1
- Impaired renal function 6
- History of IHD 12
- History of CVA/TIA 5
- Duration in hospitala (days) 4.82  3.18, 2e13
a Mean  SD, range.
b Packs/year.
c in years.patients in group-1 and the change in HbA1c level (HbA1c
level at 3 months minus HbA1c levels at baseline) in these
patients.
This study was approved by the local Helsinki committee
of the Nazareth hospital and all the patients signed a con-
sent form.Results
25 patients were enrolled in each group. 2 patients from
group-1 were unable provide a repeated sample, two pa-
tients from the control group (group-2) were given steroids
after enrollment, and 2 patients were unable to provide a
repeated HbA1c samples. So, 23 and 21 patients from
groups 1 and 2 respectively, completed the study.
Table 1 shows the characteristic of the patients in both
groups at the time of enrollment. There was no significant
difference in any parameter between the two groups,
except as expected, in PCO2 levels that was significantly
higher in group-1 patients.
Nineteen patients from group-1 were treated initially
with intravenous hydrocortisone for the COPD exacerbation
and later switched to oral prednisone. The other four pa-
tients were started on oral prednisone.
Table 2 shows the mean blood glucose levels during
hospital stay and number of patients with significant
augmentation of anti-diabetic medications and diet. As
expected, patients from group-1 had significantly higher23) Group-2 (No. of patients Z 21) P value
65.91  7.5, 48e80 0.501
19:2 >0.999
30.86  6.9, 21.79e53.41 0.460
11.8  9.46, 3e34 0.302
14 0.598
4 >0.999
5 0.622
3 0.911
19 0.930
55.25  37.96, 8e145 0.236
16 >0.999
5 0.876
1 >0.999
40.60  8.6, 29.6e50.1 0.006
94.0  5.40, 80e100 0.466
7.8%  1.8, 5.6e12.2 0.682
9.52  3.4, 5.36e19.93 0.921
3.15  4.79, 0.2e22.51 0.085
8 0.596
10 >0.999
6 0.860
3.52  3.26, 1e12 0.272
Table 2 Mean glucose levels during hospital stay and
changes in antidiabetic management in both groups.
Group
Parameter Group-1 Group-2 P value
- Mean SD glucose levels
during hospital stay (mg%)
244  96 158  74 0.003
- Patients with significant
augmentation in anti-diabetic
treatment.
18 13 0.236
- Initiation of insulin therapy. 8 3 0.117
- Patients with significant
reduction in carbohydrate diet
15 14 0.919
Table 4 Correlation between different demographic,
clinical and laboratory variables and change in HbA1c levels
in group-1 patients.
Parameter P value
- Age 0.58
- BMI at baseline 0.102
- Duration of diabetes 0.454
- Packs/year 0.350
- PCO2 levels on admission 0.422
- O2 saturation on admission 0.582
- WBC on admission 0.342
- CRP on admission 0.232
- Mean glucose levels during hospital stay 0.062
- Total dose of steroids 0.026
- Baseline HbA1c level 0.284
- Difference between BMI
(End of the study e baseline)
0.180
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patients from this group (though not significant) had
augmentation of anti-diabetic measures, including number
of patients started on insulin treatment. All the patients
from both groups following discharge, had followed the
recommendation in terms of anti-diabetic treatment and
diet with no addition of new treatment.
Table 3 shows the HbA1c values at baseline and 3 months
later in both groups, in addition to the cumulative steroid
dose in group-1 patients. There was no significant differ-
ence between the HbA1c levels in group-1 patients
(p Z 0.416), however, there was a significant decrease in
the HbA1c levels obtained 3 months after admission in
group-2 (p Z 0.032).
Table 4 summarizes the correlation between different
variables and the change in HbA1c levels in group-1 pa-
tients. Only total dose of steroids significantly correlated
with the change in HbA1c levels.
Discussion
The main finding in our study is the lack of significant
change in HbA1c levels in diabetic patients with COPD
exacerbation (group-1), 3 months following the start of
corticosteroid treatment (p Z 0.416). The lack ofTable 3 HbA1c levels at baseline and 3 months later and type
groups with cumulative dose and duration of steroid treatment i
Group
Parameter Group-1
- HbA1c at baselinea 7.7  1.52, 6.1e11
- HbA1c 3 months latera 7.6  1.59, 5.2e11.2
P valueb 0.416
- Total steroid dose (mg)a 520  302, 150e1050
- Days on systemic steroidsa 18.8  8.3, 8e40
- Type of anti-diabetic therapy by the end of the study
Oral hypoglycemic 17
Insulin alone 6
Combination 13
Die alone 0
a Mean  SD, range.
b P values within each group comparing levels of HbA1c at baselinesignificant change was despite the significantly high blood
glucose levels that were measured in group-1 following
admission. The significantly high blood glucose levels in
group-1 as compared to those in group-2 were most prob-
ably related to the corticosteroid treatment. Some stress
effect cannot be ruled out. It seems that the anti-diabetic
management of these patients, prevented significant
glycosylation of HbA1c.
These findings are very important in the sense that
physicians should not be discouraged from treating diabetic
patients with corticosteroids during COPD exacerbation.
One potential bias that may affect the results in our
study is physical activity. We did not quantify the physical
activity in both groups, however most of the patients in
both groups were relatively not young and physically
inactive.
It must be mentioned that our cohort is relatively a small
one, and studies on larger population are needed to confirm
our results.
There are very few reported studies about CIH in COPD
patients. In one study evaluating the circadian effect ofof anti-diabetic treatment at the end of the study, in both
n group-1 patients.
Group-2 P value
7.9  1.7, 5.6e12.2 0.702
7.5  1.28, 5.4e11.5 0.890
0.032
0
0
15 0.853
5 >0.999
7 0.204
1 0.9730
to those obtained 3 months later.
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glucose monitoring, 53% of those without diabetes and 100%
of those with diabetes recorded glucose levels >200 mg%
that was significantly higher than those recorded in COPD
patients without diabetes and not treated with predniso-
lone (8%) [13]. It was also found that CIH was predominantly
seen in the afternoon and evening. The same trend was
seen also in our patients (data not shown).
Both groups in our study had similar number of comor-
bidities. Other than CIH, steroids could induce hypertension
and water retention that could negatively affect these
comorbidities.
BMI is a known risk factor for insulin resistance [14],
however patients from both group-1 and group-2 were
equally obese, so obesity could not be a potential
confounder in our results.
CRP which is considered an inflammatory marker is
known to be increased in both diabetes and COPD (stable or
exacerbated) [15,16]. It was also found to correlate with
poor glycemic control and HbA1c levels [15]. Both groups in
our study had elevated CRP levels with higher levels seen,
as expected, in group-1, yet not significant (some patients
in group-2 had remarkable elevation of CRP due to sepsis).
So most probably, inflammation also was not a confounder
in our study.
Insulin treatment, either newly initiated (w35%), or
augmented, was the dominant tool in the management of
CIH in our patients, in addition to other measures like oral
hypoglycemics and diet (Table 2). Currently there is no
evidence regarding the most effective modality of treat-
ment of CIH. Different aspects need to be considered
before choosing the “appropriate” treatment of CIH,
including mechanism of CIH, type, dose, mode, frequency
and anticipated duration of the corticosteroid treatment,
level of hyperglycemia, underlying medical condition,
mechanism of actions of anti-diabetic medications and
others [9]. Current oral hypoglycemics are slow in action
and with limited hypoglycemic power. Insulin treatment is
more potent, has rapid action and with an unlimited hy-
poglycemic action.
Using multi-variate linear regression analysis (Table 4),
total dose of steroids given for the treatment of COPD
exacerbation, was found as a predictor for a change in
HbA1c levels. BMI and mean glucose levels during the
admission for COPD exacerbation were on the edge of sig-
nificance as predictors. These findings (regarding BMI and
mean glucose levels) could result from the relatively small
number of patients in our study.
In a previous study, it was found that age was a predictor
for the development of diabetes in patients without dia-
betes treated with steroids for respiratory problems [17]. In
our study, age was not a predictor for a change in HbA1c
levels, neither respiratory measures like PCO2 levels or
baseline HbA1c and CRP levels. Although both change in
HbA1c levels and development of hyperglycemia or dia-
betes correlate with glucose homeostasis, these two en-
tities are not synonyms, and a predictor for one entity
might not be good enough as a predictor for the other en-
tity. Again, our small cohort might have contributed to the
lack of significance.
Unfortunately insulin levels were not obtained in our
study in order to evaluate insulin resistance (IR) usinghomeoatasis model assessment (HOMA-IR). Such measure-
ments would shed more light on the level of insulin resis-
tance vs. decreased insulin secretion behind CIH, and might
help in directing appropriate treatment for CIH in diabetic
patients with COPD exacerbation. However, insulin treat-
ment and uncontrolled hyperglycemia could hamper the
validity of HOMA-IR [18].
It is interesting to note that although inter-group com-
parison between group-1 and group-2 patients regarding
HbA1c levels at both baseline and 3 months later, showed
no significant difference between the two groups (Table 3),
intra-group comparison in group-2 patients showed a sig-
nificant decrease in HbA1c levels obtained 3 months
following admission, compared to those at baseline
(p Z 0.032). This observation could be the result of the
augmentation of anti-diabetic measures in these patients
(Table 2) at the presence of significantly lower blood
glucose levels (compared to group-1), following admission
to the hospital. Intensive blood glucose monitoring is a
routine medical practice in our ward, as in most medical
wards, for diabetic patients regardless for the reason of
admission. Such a routine monitoring, along with goals for
lower blood glucose levels towards normal levels, had led
most probably to tighter control of diabetes in group-2
patients and to significantly lower HbA1c levels.
There is no data in the literature about the faith of
HbA1c levels in diabetics admitted to medical wards for
different reasons, not requiring corticosteroid treatment.
Such studies are needed. The results from this group of
patients in our study (group-2), suggest that potentially,
diabetic patients who are admitted with COPD exacerba-
tion to the medical word, could end with even lower HbA1c
levels 3 months later, provided that more aggressive anti-
diabetic treatment was used, especially insulin therapy, in
order to curb CIH.
Conclusions
Corticosteroid treatment was not associated with a signifi-
cant increase in HbA1c in diabetic patients with COPD
exacerbation. Physicians should not be discouraged from
using corticosteroids in such situations. The expected rise
of blood glucose levels following corticosteroid treatment,
should be treated aggressively, mainly with insulin therapy.
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